{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:57:43Z","timestamp":1768442263696,"version":"3.49.0"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/wco.0b013e3282f4098e","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T05:40:52Z","timestamp":1236231652000},"page":"8-15","source":"Crossref","is-referenced-by-count":58,"title":["Ocular myasthenia: diagnostic and treatment recommendations and the evidence base"],"prefix":"10.1097","volume":"21","author":[{"given":"Uladzimir","family":"Luchanok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry J","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210206","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"R2-4-20210206","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"R3-4-20210206","first-page":"93","article-title":"Clinical presentation and epidemiology of myasthenia gravis","author":"Kuks","year":"2003"},{"key":"R4-4-20210206","first-page":"146","article-title":"Diagnosis of myasthenia gravis","author":"Seybold","year":"1999"},{"key":"R5-4-20210206","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.nrl.0000240856.03505.b5","article-title":"Ocular myasthenia: diagnosis, treatment, and pathogenesis","volume":"12","author":"Kusner","year":"2006","journal-title":"Neurologist"},{"key":"R6-4-20210206","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ohc.2004.05.014","article-title":"Ocular myasthenia gravis.","volume":"17","author":"Elrod","year":"2004","journal-title":"Ophthalmol Clin North Am"},{"key":"R7-4-20210206","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-2000-6829","article-title":"Ocular aspects of myasthenia gravis","volume":"20","author":"Barton","year":"2000","journal-title":"Semin Neurol"},{"key":"R8-4-20210206","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients","volume":"244","author":"Beekman","year":"1997","journal-title":"J Neurol"},{"key":"R9-4-20210206","first-page":"115","article-title":"Ocular myasthenia","author":"Daroff","year":"2003"},{"key":"R10-4-20210206","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of ocular myasthenia","volume":"14","author":"Bever","year":"1983","journal-title":"Ann Neurol"},{"key":"R11-4-20210206","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"key":"R12-4-20210206","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis","volume":"52","author":"Oosterhuis","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R13-4-20210206","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","article-title":"Ocular myasthenia: diagnostic and therapeutic problems","volume":"77","author":"Evoli","year":"1988","journal-title":"Acta Neurol Scand"},{"key":"R14-4-20210206","first-page":"131","article-title":"Natural history of myasthenia gravis","author":"Grob","year":"1999"},{"key":"R15-4-20210206","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1212\/WNL.45.11.2065","article-title":"Saccadic duration and intrasaccadic fatigue in myasthenic and nonmyasthenic ocular palsies","volume":"45","author":"Barton","year":"1995","journal-title":"Neurology"},{"key":"R16-4-20210206","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1212\/WNL.57.12.2163","article-title":"ANT1, Twinkle, POLG, and TP: new genes open our eyes to ophthalmoplegia","volume":"57","author":"Hirano","year":"2001","journal-title":"Neurology"},{"key":"R17-4-20210206","article-title":"The neurology of eye movements. 3rd ed","author":"Leigh","year":"1999"},{"key":"R18-4-20210206","first-page":"25","article-title":"Ocular myasthenia gravis","volume":"6","author":"Fouladvand","year":"2005","journal-title":"Compr Opthalmol Update"},{"key":"R20-4-20210206","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/123.4.665","article-title":"The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK","volume":"123","author":"MacDonald","year":"2000","journal-title":"Brain"},{"key":"R21-4-20210206","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1212\/WNL.42.10.1888","article-title":"The epidemiology of myasthenia gravis in central and western Virginia","volume":"42","author":"Phillips","year":"1992","journal-title":"Neurology"},{"key":"R22-4-20210206","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1212\/WNL.47.5.1233","article-title":"Epidemiologic evidence for a changing natural history of myasthenia gravis","volume":"47","author":"Phillips","year":"1996","journal-title":"Neurology"},{"key":"R23-4-20210206","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/archneur.1991.00530190081019","article-title":"Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive study","volume":"48","author":"Somnier","year":"1991","journal-title":"Arch Neurol"},{"key":"R24-4-20210206","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/WNL.43.9.1779","article-title":"Incidence and prevalence of myasthenia gravis in western Denmark 1975 to 1989","volume":"43","author":"Christensen","year":"1993","journal-title":"Neurology"},{"key":"R25-4-20210206","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1196\/annals.1254.054","article-title":"Myasthenia gravis (MG): epidemiological data and prognostic factors","volume":"998","author":"Mantegazza","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R26-4-20210206","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2169\/internalmedicine.44.572","article-title":"Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan","volume":"44","author":"Matsuda","year":"2005","journal-title":"Intern Med"},{"key":"R27-4-20210206","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","article-title":"Evidence of underdiagnosis of myasthenia gravis in older people","volume":"74","author":"Vincent","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R28-4-20210206","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1212\/WNL.37.12.1854","article-title":"Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians","volume":"37","author":"Chiu","year":"1987","journal-title":"Neurology"},{"key":"R29-4-20210206","first-page":"235","article-title":"Possible evidence of a variant of myasthenia gravis based on HLA and acetylcholine receptor antibody in Chinese patients","volume":"70","author":"Hawkins","year":"1989","journal-title":"QJM"},{"key":"R30-4-20210206","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1600-0404.1992.tb08056.x","article-title":"Myasthenia gravis in Hong Kong Chinese","volume":"86","author":"Wong","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"R32-4-20210206","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archneur.1986.00520080081029","article-title":"The office tensilon test for ocular myasthenia gravis","volume":"43","author":"Daroff","year":"1986","journal-title":"Arch Neurol"},{"key":"R33-4-20210206","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-2003-40755","article-title":"The edrophonium test","volume":"23","author":"Pascuzzi","year":"2003","journal-title":"Semin Neurol"},{"key":"R34-4-20210206","first-page":"45","article-title":"Comparison of diagnostic tests in myasthenia gravis","volume":"19","author":"Nicholson","year":"1983","journal-title":"Clin Exp Neurol"},{"key":"R36-4-20210206","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S0161-6420(99)00709-5","article-title":"An ice test for the diagnosis of myasthenia gravis","volume":"106","author":"Golnik","year":"1999","journal-title":"Ophthalmology"},{"key":"R37-4-20210206","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1067\/mpa.2000.106204","article-title":"Extraocular muscle responses to orbital cooling (ice test) for ocular myasthenia gravis diagnosis","volume":"4","author":"Ellis","year":"2000","journal-title":"J AAPOS"},{"key":"R38-4-20210206","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"R39-4-20210206","first-page":"288","article-title":"The sleep test for myasthenia gravis. Safe alternative to Tensilon","volume":"11","author":"Odell","year":"1991","journal-title":"J Clin Neurol Ophthalmol"},{"key":"R40-4-20210206","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0161-6420(00)00458-9","article-title":"The ice test versus the rest test in myasthenia gravis","volume":"107","author":"Kubis","year":"2000","journal-title":"Ophthalmology"},{"key":"R41-4-20210206","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 5","key":"R42-4-20210206","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1212\/WNL.48.Suppl_5.23S","article-title":"Serologic profile of myasthenia gravis and distinction from Lambert\u2013Eaton myasthenic syndrome","volume":"48","author":"Lennon","year":"1997","journal-title":"Neurology"},{"key":"R43-4-20210206","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneur.62.6.1002","article-title":"Anti-MuSK myasthenia gravis presenting with purely ocular findings","volume":"62","author":"Caress","year":"2005","journal-title":"Arch Neurol"},{"key":"R44-4-20210206","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/bjo.2006.108498","article-title":"Ocular myasthenia: a rare presentation with MuSK antibody and bilateral extraocular muscle atrophy","volume":"91","author":"Chan","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R45-4-20210206","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/jnnp.2005.075812","article-title":"Anti-MuSK antibodies in a case of ocular myasthenia gravis","volume":"77","author":"Bennett","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R46-4-20210206","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"R47-4-20210206","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.20069","article-title":"Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients","volume":"30","author":"Zhou","year":"2004","journal-title":"Muscle Nerve"},{"key":"R48-4-20210206","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol"},{"key":"R49-4-20210206","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mus.1218","article-title":"The agrin\/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction","volume":"25","author":"Liyanage","year":"2002","journal-title":"Muscle Nerve"},{"key":"R50-4-20210206","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"R51-4-20210206","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2004-829594","article-title":"Myasthenia gravis: diagnosis","volume":"24","author":"Meriggioli","year":"2004","journal-title":"Semin Neurol"},{"key":"R52-4-20210206","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0733-8619(01)00012-3","article-title":"An electrodiagnostic approach to the patient with neuromuscular junction disorder","volume":"20","author":"Katirji","year":"2002","journal-title":"Neurol Clin"},{"key":"R53-4-20210206","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S0317167100049040","article-title":"Usefulness of single fiber EMG for distinguishing neuromuscular from other causes of ocular muscle weakness","volume":"21","author":"Ukachoke","year":"1994","journal-title":"Can J Neurol Sci"},{"key":"R54-4-20210206","doi-asserted-by":"crossref","first-page":"397","DOI":"10.33588\/rn.4407.2006442","article-title":"[Ocular myasthenia gravis: diagnostic aspects and evolution]","volume":"44","author":"De Entrambasaguas","year":"2007","journal-title":"Rev Neurol"},{"key":"R55-4-20210206","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1567-424X(09)70354-X","article-title":"Electrophysiologic tests of neuromuscular transmission","volume":"57","author":"Sanders","year":"2004","journal-title":"Suppl Clin Neurophysiol"},{"key":"R56-4-20210206","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/(SICI)1097-4598(199609)19:9<1069::AID-MUS1>3.0.CO;2-Y","article-title":"AAEM minimonograph #25: single-fiber electromyography","volume":"19","author":"Sanders","year":"1996","journal-title":"Muscle Nerve"},{"key":"R57-4-20210206","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","article-title":"Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"68","author":"Benatar","year":"2007","journal-title":"Neurology"},{"key":"R58-4-20210206","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000310681","article-title":"Strabismus surgery in ocular myasthenia gravis","volume":"210","author":"Ohtsuki","year":"1996","journal-title":"Ophthalmologica"},{"key":"R59-4-20210206","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/eye.2001.6","article-title":"Active management in patients with ocular manifestations of myasthenia gravis","volume":"15","author":"Bentley","year":"2001","journal-title":"Eye"},{"key":"R60-4-20210206","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01215447","article-title":"Ocular myasthenia gravis, a critical review of clinical and pathophysiological aspects","volume":"84","author":"Sommer","year":"1993","journal-title":"Doc Ophthalmol"},{"key":"R61-4-20210206","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R62-4-20210206","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","article-title":"Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment","volume":"89","author":"Kupersmith","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R63-4-20210206","first-page":"13","article-title":"Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis","volume":"25","author":"Chirapapaisan","year":"2007","journal-title":"Asian Pac J Allergy Immunol"},{"key":"R64-4-20210206","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis","volume":"23","author":"Mee","year":"2003","journal-title":"J Neuroophthalmol"},{"key":"R65-4-20210206","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archneur.60.10.1491-b","article-title":"Development of generalized myasthenia gravis in patients with ocular myasthenia gravis","volume":"60","author":"Papapetropoulos","year":"2003","journal-title":"Arch Neurol"},{"key":"R66-4-20210206","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00063030-200115060-00003","article-title":"Immunosuppressive treatment of ocular myasthenia gravis","volume":"15","author":"Tackenberg","year":"2001","journal-title":"BioDrugs"},{"key":"R67-4-20210206","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneur.57.5.752","article-title":"Controversies in neurology. Treatment of ocular myasthenia: steroids only when compelled","volume":"57","author":"Kaminski","year":"2000","journal-title":"Arch Neurol"},{"key":"R68-4-20210206","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/archneur.57.5.750","article-title":"Treatment of ocular myasthenia with corticosteroids: yes","volume":"57","author":"Agius","year":"2000","journal-title":"Arch Neurol"},{"key":"R69-4-20210206","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2003.10.014","article-title":"Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?","volume":"217","author":"Kupersmith","year":"2004","journal-title":"J Neurol Sci"},{"key":"R70-4-20210206","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J Neurol Sci"},{"key":"R71-4-20210206","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0303-8467(02)00104-X","article-title":"Relapse of ocular symptoms after remission of myasthenia gravis \u2013 a comparison of relapsed and complete remission cases","volume":"105","author":"Wakata","year":"2003","journal-title":"Clin Neurol Neurosurg"},{"key":"R72-4-20210206","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"R73-4-20210206","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00314245","article-title":"Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis","volume":"235","author":"Mantegazza","year":"1988","journal-title":"J Neurol"},{"key":"R74-4-20210206","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/WNL.38.2.258","article-title":"Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis","volume":"38","author":"Hohlfeld","year":"1988","journal-title":"Neurology"},{"key":"R75-4-20210206","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1749-6632.1981.tb33767.x","article-title":"Effect of immunosuppressive drugs (azathioprine)","volume":"377","author":"Mertens","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"R76-4-20210206","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1749-6632.1987.tb51327.x","article-title":"Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis","volume":"505","author":"Matell","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"R77-4-20210206","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"key":"R78-4-20210206","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"R79-4-20210206","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"key":"R80-4-20210206","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"key":"R81-4-20210206","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study","volume":"998","author":"Meriggioli","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R82-4-20210206","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R83-4-20210206","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jnnp.48.4.332","article-title":"Thymectomy in myasthenia with pure ocular symptoms","volume":"48","author":"Schumm","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R84-4-20210206","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1067\/mtc.2001.116191","article-title":"Thymectomy in the treatment of ocular myasthenia gravis","volume":"122","author":"Roberts","year":"2001","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0b013e3282f4098e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:09:37Z","timestamp":1738976977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-200802000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e3282f4098e","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}